Mohammad Yousaf, Fiaza Javed, Sahibzada Muhammad Jawad, Rukhsana Naz, Anam Anam, Izhar Ullah
Cadmium induces neurotoxicity in brain and results in increased enzymatic functions, accumulation of Amyloid beta plaque and Neuo Fibrillary Tangles (NFTs) causing neurodegenerative diseases. The purpose of the present work was to investigate the anti-inflammatory or anti-oxidative potential of vitaminB12 against Cd -induced memory impairment and mechanism of signaling pathway of vitamin-B12 protection in Cd-induced neuroinflammatory in mice model. Male albino mice of BALB/C trait of age 7 to 8 weeks and weighing about (30-32±3g) were used as model animal in the study. All mice were divided in three groups. Control Group (CG) treated with 0.9% saline (1mL/Kg), Cd Cl2 administered Group (CD) (1mg/kg) and Cd +Vitamin administered group (CV) B-12 (500µg/kg). CD group was treated with Cd Cl2 for three weeks on alternate days while CV group was treated with Vitamin B12 and toxin CdCl2 for the next two weeks intraperitonealy. Behavior tests like Morris Water Maze (MWM) and Y-Maze (YM) tests were conducted on the experimental mice to study the neuro protective potential of Vitamin-B12 against CdCl2 induced memory dysfunctions. After completing the above procedures, mice were sacrificed and the brains of each group were collected for protein quantification step and western blotting. The Immuno blots of Iba-1, NF-kB, TNF-α, IL-1β, BACE1 and Aβ proteins in the brain homogenates of CD and CV mice confirm the anti-neuroinflammatory potential of vitamin-B12 against Cadmium –induced Neuroinflammation. Escape latency of CV group mice receiving Methylcobalamine was less and showed better performance in MWM test. The results of Y-maze test also showed that the spontaneous percentage alternation of CD group mice was less than CV and CG group of mice. Immuno blot of p-Akt confirm the signaling pathways of vitamin-B12 protection in Cd-induced neuroinflammatory mediated memory-impairment in the model mice. Our findings suggest that Vitamin-B12 could be a potent candidate drug for treating cognitive dysfunctions due to its anti-inflammatory and anti-oxidative potential. Our study also shows that Vitamin-B12 activates p-Akt signaling pathway along with decreasing the NF-Κb, TNF-α and IL-1β to protect the brain of mice against CdCl2 neurotoxicity.
{"title":"Neuroprotective Potential of Vitamin B-12 Against Cadmium–Induced Neuroinflammation Mediated Memory Dysfunctions in Adult Albino Mice","authors":"Mohammad Yousaf, Fiaza Javed, Sahibzada Muhammad Jawad, Rukhsana Naz, Anam Anam, Izhar Ullah","doi":"10.22146/ijp.4854","DOIUrl":"https://doi.org/10.22146/ijp.4854","url":null,"abstract":"Cadmium induces neurotoxicity in brain and results in increased enzymatic functions, accumulation of Amyloid beta plaque and Neuo Fibrillary Tangles (NFTs) causing neurodegenerative diseases. The purpose of the present work was to investigate the anti-inflammatory or anti-oxidative potential of vitaminB12 against Cd -induced memory impairment and mechanism of signaling pathway of vitamin-B12 protection in Cd-induced neuroinflammatory in mice model. Male albino mice of BALB/C trait of age 7 to 8 weeks and weighing about (30-32±3g) were used as model animal in the study. All mice were divided in three groups. Control Group (CG) treated with 0.9% saline (1mL/Kg), Cd Cl2 administered Group (CD) (1mg/kg) and Cd +Vitamin administered group (CV) B-12 (500µg/kg). CD group was treated with Cd Cl2 for three weeks on alternate days while CV group was treated with Vitamin B12 and toxin CdCl2 for the next two weeks intraperitonealy. Behavior tests like Morris Water Maze (MWM) and Y-Maze (YM) tests were conducted on the experimental mice to study the neuro protective potential of Vitamin-B12 against CdCl2 induced memory dysfunctions. After completing the above procedures, mice were sacrificed and the brains of each group were collected for protein quantification step and western blotting. The Immuno blots of Iba-1, NF-kB, TNF-α, IL-1β, BACE1 and Aβ proteins in the brain homogenates of CD and CV mice confirm the anti-neuroinflammatory potential of vitamin-B12 against Cadmium –induced Neuroinflammation. Escape latency of CV group mice receiving Methylcobalamine was less and showed better performance in MWM test. The results of Y-maze test also showed that the spontaneous percentage alternation of CD group mice was less than CV and CG group of mice. Immuno blot of p-Akt confirm the signaling pathways of vitamin-B12 protection in Cd-induced neuroinflammatory mediated memory-impairment in the model mice. Our findings suggest that Vitamin-B12 could be a potent candidate drug for treating cognitive dysfunctions due to its anti-inflammatory and anti-oxidative potential. Our study also shows that Vitamin-B12 activates p-Akt signaling pathway along with decreasing the NF-Κb, TNF-α and IL-1β to protect the brain of mice against CdCl2 neurotoxicity.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Different approaches are being in the practice for the topical application of antifungal drugs, although in a few cases, they have been found less efficient because of their poor cutaneous availability and permeability. Luliconazole (LUL) is one of the antifungal medications that is being used for the treatment of various superficial infections. The poor permeability of LUL is regarded to be a factor for its reduced efficacy. Hence, the current study aimed to develop a nanosponge hydrogel that would improve dermal availability and permeability. A set of nanosponge formulations (L1-L18) were designed with the help of central composite design (Design Expert 13, state ease Inc., Minneapolis, MN, USA). L1-L18 was prepared by using the emulsion solvent evaporation technique. The nanosponges were characterized for drug-excipient compatibility (FTIR, P-XRD, and DSC), and particle size, polydispersibility index, zeta potential, entrapment efficiency (EE), and in vitro drug release; further optimized. The optimized nanosponge formulation (L18) was taken to produce six hydrogels (LF1-LF6) of LUL by varied proportions of the gelling agent. In this process, initially, the gel was constituted with Carbopol 934/ sodium CMC/HPMC. Later, attained hydrogel texture was evaluated for its viscosity, swelling, and membrane permeability, followed by in vitro drug release, and antifungal efficacy study. The nanosponge formulations (L1-L17) had an average particle size of 109±0.45 to 386±0.34 nm, entrapment efficiency of 35.45±0.46- 89.65±0.37 % with 84.67±0.54 -99.65±0.48 % of drug release for 8 h. The formulation L18 was predicted with better responses in particle size, EE, and drug release i.e., 378±0.25 nm, 84.65±0.45%, and of 96.18±0.54%, respectively for 8 h. Out of six formulated nanosponge gels (LF1-LF6), LF2 showed an optimal viscosity (25.69 ±0.45 pa.S), pH (6.87±0.56) and % drug release (80.65 ±0.64%) in 8 h. Drug release was governed by non-fickian diffusion mechanisms and zero-order. Developed nanosponge hydrogel was found as stable and had a high rate of permeation with better retention which can be effective enough in topical applications.
{"title":"Formulation Formulation and Evaluation of Luliconazole nanosponge gel using Experimental design","authors":"Narender Malothu, Sadhana Noothi, Anka Rao Areti, Vishnu Pulavarthy","doi":"10.22146/ijp.7692","DOIUrl":"https://doi.org/10.22146/ijp.7692","url":null,"abstract":"Different approaches are being in the practice for the topical application of antifungal drugs, although in a few cases, they have been found less efficient because of their poor cutaneous availability and permeability. Luliconazole (LUL) is one of the antifungal medications that is being used for the treatment of various superficial infections. The poor permeability of LUL is regarded to be a factor for its reduced efficacy. Hence, the current study aimed to develop a nanosponge hydrogel that would improve dermal availability and permeability. A set of nanosponge formulations (L1-L18) were designed with the help of central composite design (Design Expert 13, state ease Inc., Minneapolis, MN, USA). L1-L18 was prepared by using the emulsion solvent evaporation technique. The nanosponges were characterized for drug-excipient compatibility (FTIR, P-XRD, and DSC), and particle size, polydispersibility index, zeta potential, entrapment efficiency (EE), and in vitro drug release; further optimized. The optimized nanosponge formulation (L18) was taken to produce six hydrogels (LF1-LF6) of LUL by varied proportions of the gelling agent. In this process, initially, the gel was constituted with Carbopol 934/ sodium CMC/HPMC. Later, attained hydrogel texture was evaluated for its viscosity, swelling, and membrane permeability, followed by in vitro drug release, and antifungal efficacy study. The nanosponge formulations (L1-L17) had an average particle size of 109±0.45 to 386±0.34 nm, entrapment efficiency of 35.45±0.46- 89.65±0.37 % with 84.67±0.54 -99.65±0.48 % of drug release for 8 h. The formulation L18 was predicted with better responses in particle size, EE, and drug release i.e., 378±0.25 nm, 84.65±0.45%, and of 96.18±0.54%, respectively for 8 h. Out of six formulated nanosponge gels (LF1-LF6), LF2 showed an optimal viscosity (25.69 ±0.45 pa.S), pH (6.87±0.56) and % drug release (80.65 ±0.64%) in 8 h. Drug release was governed by non-fickian diffusion mechanisms and zero-order. Developed nanosponge hydrogel was found as stable and had a high rate of permeation with better retention which can be effective enough in topical applications.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Yulyana, Chaidir Amin, Partomuan Simanjuntak, Syamsudin Abdillah, Abdul Rohman, Eko Mugiyanto
The objective of the current study was to evaluate the antimetabolite activity of anthocyanins in Cantigi fruits from two Indonesian conservation areas. Cantigi (Vaccinium varingiaefolium) is a native fruit species known for its rich anthocyanin content associated with various health benefits. However, more research needs to be conducted on the antimetabolite properties of these anthocyanins. This study collected Cantigi fruits from two conservation sites in Indonesia, Tangkuban Perahu (CTP) and Papandayan (CPP) Mountain, and the antimetabolite activity was evaluated using enzymatic assays. The results demonstrated significant antimetabolite activity of CTP, particularly in inhibiting α-Glucosidase (53.72±1,98 µg/ml), pancreatic lipase (110.48±2,13 µg/ml), and angiotensin-converting enzyme (27.32±1,24 µg/ml). Furthermore, our analysis using HRMS revealed the presence of three anthocyanin compounds, delphinidin, malvidin, and peonidin, which are believed to contribute to the observed antimetabolite activities of Cantigi. These findings provide valuable insights into the specific compounds responsible for the bioactivity of Cantigi and further support its potential as a natural source of bioactive substances. Future research should focus on elucidating the molecular mechanisms underlying the effects of these anthocyanins on the targeted enzymes and exploring their potential synergistic interactions.
{"title":"Assessing the Antimetabolite Activity of Anthocyanins in Cantigi Fruits from Two Conservation Sites in Indonesia","authors":"Ana Yulyana, Chaidir Amin, Partomuan Simanjuntak, Syamsudin Abdillah, Abdul Rohman, Eko Mugiyanto","doi":"10.22146/ijp.8788","DOIUrl":"https://doi.org/10.22146/ijp.8788","url":null,"abstract":"The objective of the current study was to evaluate the antimetabolite activity of anthocyanins in Cantigi fruits from two Indonesian conservation areas. Cantigi (Vaccinium varingiaefolium) is a native fruit species known for its rich anthocyanin content associated with various health benefits. However, more research needs to be conducted on the antimetabolite properties of these anthocyanins. This study collected Cantigi fruits from two conservation sites in Indonesia, Tangkuban Perahu (CTP) and Papandayan (CPP) Mountain, and the antimetabolite activity was evaluated using enzymatic assays. The results demonstrated significant antimetabolite activity of CTP, particularly in inhibiting α-Glucosidase (53.72±1,98 µg/ml), pancreatic lipase (110.48±2,13 µg/ml), and angiotensin-converting enzyme (27.32±1,24 µg/ml). Furthermore, our analysis using HRMS revealed the presence of three anthocyanin compounds, delphinidin, malvidin, and peonidin, which are believed to contribute to the observed antimetabolite activities of Cantigi. These findings provide valuable insights into the specific compounds responsible for the bioactivity of Cantigi and further support its potential as a natural source of bioactive substances. Future research should focus on elucidating the molecular mechanisms underlying the effects of these anthocyanins on the targeted enzymes and exploring their potential synergistic interactions.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indra Gunawan, Budi Setiadi Daryono, Eka Noviana, T N Saifullah Sulaiman
Nano-perfume is an alcohol-free perfume in the form of oil-in-water nanoemulsions containing fragrance. Due to its favorable properties, nano-perfume may appeal to a broader client base, including children and individuals with sensitive skin. This technology can provide an alternative solution to the low permanence of fragrances by eliminating ethanol and decreasing the amount of surfactant, co-surfactant, and solvents used in the formulation. However, relatively few researchers have studied and developed this technology to date. In this review, we examine several essential elements of nano-perfume, therefore it is hoped that relevant questions will be raised regarding the future of this technology. The discussion is focused on the definition and composition of perfume, the notion of "notes" in fragrances products, nanotechnology in the cosmetics industry, significant characteristics of nano-perfume, as well as problems and prospects.
{"title":"Nano-Perfumes As A Fragrance Carrier: Their Brief History, Essential Aspects, Development, Preparation Methods, Characteristics, And Future Perspectives","authors":"Indra Gunawan, Budi Setiadi Daryono, Eka Noviana, T N Saifullah Sulaiman","doi":"10.22146/ijp.6652","DOIUrl":"https://doi.org/10.22146/ijp.6652","url":null,"abstract":"Nano-perfume is an alcohol-free perfume in the form of oil-in-water nanoemulsions containing fragrance. Due to its favorable properties, nano-perfume may appeal to a broader client base, including children and individuals with sensitive skin. This technology can provide an alternative solution to the low permanence of fragrances by eliminating ethanol and decreasing the amount of surfactant, co-surfactant, and solvents used in the formulation. However, relatively few researchers have studied and developed this technology to date. In this review, we examine several essential elements of nano-perfume, therefore it is hoped that relevant questions will be raised regarding the future of this technology. The discussion is focused on the definition and composition of perfume, the notion of \"notes\" in fragrances products, nanotechnology in the cosmetics industry, significant characteristics of nano-perfume, as well as problems and prospects.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hadeel Delman Najim, None Mohammed Mahmood Mohammed, None Abbas Mahdi Rahmah
Evaluate the efficacy of dapagliflozin on glycaemic and non-glycaemic indices and assess quality of life in type 2 diabetes patients (T2DM) with inadequate glycaemic control on three oral antidiabetic agents (OADs). Patients with uncontrolled type 2 diabetes [Haemoglobin A1c 7.0%-12.0%] on sulfonylurea, metformin and gliptin were selected to receive dapagliflozin 5mg/day for 16 weeks (n=40). Fasting and postprandial plasma glucose, glycated haemoglobin A1c, body weight, and waist circumference were measured. Assessment of patients’ quality of life was performed using Quality of Life Scale for Iraqi Diabetic patients (QOLSID) at baseline and after administration of dapagliflozin. Dapagliflozin showed high significant reduction in fasting and postprandial plasma glucose, glycated haemoglobin A1c (HbA1c), body mass index (BMI) and index of central obesity (ICO) (p<0.001). High significant changes in the QOLSID score after treatment (p<0.001). High BMI is negative predictor for patients’ quality of life. Dapagliflozin improved both glycaemic and non-glycaemic parameters in T2DM patients who already on three OADs. This is promising results in short period makes the treatment a suitable alternative to insulin specially in patients not prefer to use injected medication. Dapagliflozin showed an improvement in the patients’ physical and psychological condition and consequently overall QOL.
{"title":"Impact of Dapagliflozin as add-on therapy on glycemic status and quality of life in type 2 diabetic patients","authors":"Hadeel Delman Najim, None Mohammed Mahmood Mohammed, None Abbas Mahdi Rahmah","doi":"10.22146/ijp.8501","DOIUrl":"https://doi.org/10.22146/ijp.8501","url":null,"abstract":"Evaluate the efficacy of dapagliflozin on glycaemic and non-glycaemic indices and assess quality of life in type 2 diabetes patients (T2DM) with inadequate glycaemic control on three oral antidiabetic agents (OADs). Patients with uncontrolled type 2 diabetes [Haemoglobin A1c 7.0%-12.0%] on sulfonylurea, metformin and gliptin were selected to receive dapagliflozin 5mg/day for 16 weeks (n=40). Fasting and postprandial plasma glucose, glycated haemoglobin A1c, body weight, and waist circumference were measured. Assessment of patients’ quality of life was performed using Quality of Life Scale for Iraqi Diabetic patients (QOLSID) at baseline and after administration of dapagliflozin. Dapagliflozin showed high significant reduction in fasting and postprandial plasma glucose, glycated haemoglobin A1c (HbA1c), body mass index (BMI) and index of central obesity (ICO) (p<0.001). High significant changes in the QOLSID score after treatment (p<0.001). High BMI is negative predictor for patients’ quality of life. Dapagliflozin improved both glycaemic and non-glycaemic parameters in T2DM patients who already on three OADs. This is promising results in short period makes the treatment a suitable alternative to insulin specially in patients not prefer to use injected medication. Dapagliflozin showed an improvement in the patients’ physical and psychological condition and consequently overall QOL.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah Puspita Atmaja, Dwi Aris Agung Nugrahaningsih, Ellsya Angeline Rawar, None Ani Kristiyani, Ahmad Hamim Sadewa, Dita Maria Virginia
A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. This study will carry out more research to ascertain which SNPs have the most influence on the effectiveness of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms "calcium channel blocker," "efficacy," "blood pressure response," "pharmacokinetic," and "polymorphism" OR "genetic" OR "genomic" to find pertinent articles. When prescription antihypertensive medications, particularly calcium channel blockers, it is important to take into account certain gene variants for example CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T , RyR3 gene rs877087 because of their considerable effects.
{"title":"Impact of Gene Polymorphism on Pharmacokinetics and Pharmaco-dynamics of Calcium Channel Blockers: A Narrative Review","authors":"Sarah Puspita Atmaja, Dwi Aris Agung Nugrahaningsih, Ellsya Angeline Rawar, None Ani Kristiyani, Ahmad Hamim Sadewa, Dita Maria Virginia","doi":"10.22146/ijp.5283","DOIUrl":"https://doi.org/10.22146/ijp.5283","url":null,"abstract":"A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. This study will carry out more research to ascertain which SNPs have the most influence on the effectiveness of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms \"calcium channel blocker,\" \"efficacy,\" \"blood pressure response,\" \"pharmacokinetic,\" and \"polymorphism\" OR \"genetic\" OR \"genomic\" to find pertinent articles. When prescription antihypertensive medications, particularly calcium channel blockers, it is important to take into account certain gene variants for example CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T , RyR3 gene rs877087 because of their considerable effects.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chuyen Le, Thi Minh Hoa Nguyen, Thi Kim Cuc Ngo, Thi Thuy Nhi Tran
Poor adherence to antidiabetic medication, which causes diabetes-related complications and increases medical burden, has been an important concern for both patients and physicians. Enhancing patients' beliefs about medicine can partially improve their non-adherence status to medications. To evaluate the factors associated with beliefs about antidiabetic medicine in outpatients with type 2 diabetes at Hue University Hospital. A cross-sectional study was conducted on 396 outpatients diagnosed with type 2 diabetes mellitus at the Endocrinology Clinic at Hue University Hospital. We interviewed the patients using a questionnaire based on the Vietnamese version of the Beliefs about Medicines Questionnaire (BMQ-V). The study was conducted on 396 patients with type 2 diabetes, with a median age of 66.9 ± 13.7 years. The prevalence of outpatients achieving HbA1C and glycemic targets was 18.7% and 20.7%, respectively. According to the BMQ-V questionnaire, the participants’ beliefs about medicine had a mean score of 50.3 ± 8.1. The mean value of the Specific-Concerns subscale was the highest (14.5 ± 3.8) and the Specific-Necessity subscale was the lowest (9.8 ± 3.9). Multivariate regression analysis revealed a statistically significant association between BMQ score and HbA1c control status, duration of diabetes, and home blood glucose monitoring (p < 0.05). Coordination between clinical pharmacists and physicians should be strengthened to improve their positive beliefs and gradually reduce their negative beliefs about medicines, thereby increasing medication adherence and improving treatment effectiveness.
{"title":"Evaluation of factors associated with beliefs about antidiabetic medicine in outpatients with type 2 diabetes at Hue University Hospital","authors":"Chuyen Le, Thi Minh Hoa Nguyen, Thi Kim Cuc Ngo, Thi Thuy Nhi Tran","doi":"10.22146/ijp.6871","DOIUrl":"https://doi.org/10.22146/ijp.6871","url":null,"abstract":"Poor adherence to antidiabetic medication, which causes diabetes-related complications and increases medical burden, has been an important concern for both patients and physicians. Enhancing patients' beliefs about medicine can partially improve their non-adherence status to medications. To evaluate the factors associated with beliefs about antidiabetic medicine in outpatients with type 2 diabetes at Hue University Hospital. A cross-sectional study was conducted on 396 outpatients diagnosed with type 2 diabetes mellitus at the Endocrinology Clinic at Hue University Hospital. We interviewed the patients using a questionnaire based on the Vietnamese version of the Beliefs about Medicines Questionnaire (BMQ-V). The study was conducted on 396 patients with type 2 diabetes, with a median age of 66.9 ± 13.7 years. The prevalence of outpatients achieving HbA1C and glycemic targets was 18.7% and 20.7%, respectively. According to the BMQ-V questionnaire, the participants’ beliefs about medicine had a mean score of 50.3 ± 8.1. The mean value of the Specific-Concerns subscale was the highest (14.5 ± 3.8) and the Specific-Necessity subscale was the lowest (9.8 ± 3.9). Multivariate regression analysis revealed a statistically significant association between BMQ score and HbA1c control status, duration of diabetes, and home blood glucose monitoring (p < 0.05). Coordination between clinical pharmacists and physicians should be strengthened to improve their positive beliefs and gradually reduce their negative beliefs about medicines, thereby increasing medication adherence and improving treatment effectiveness.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135492496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prescription drug cost-sharing in Indonesia remains challenging because no valid willingness-to-pay (WTP) questionnaire for this cost-sharing is available. The aim of this study was to conduct item selection and evaluate the content validity of the questionnaire on the WTP for prescription drug cost-sharing under the national health insurance scheme in patients with catastrophic illnesses. The method was a cross-sectional study and used a three-step design, namely literature review, consultation with some health economics experts, and evaluation of content validity. This study involved 9 experts, consisting of academicians and health professionals who worked in a hospital, to perform content validation of a questionnaire on the WTP for prescription drug cost-sharing. This study used CVI (content validity index) and CVR (content validity ratio) for both individual item measurement and the overall scale. This study's results reveal a questionnaire comprising 47 items grouped into five domains: healthcare utilization information, participation in health insurance information, drug information, and cost-sharing scenarios. The questionnaire items were extracted from many sources. The items that could be used for the study should have an I-CVI of 0.79-1.00. There were three items removed because of criticisms from the experts and Item-CVI<0.79 and CVR<0.62. Those with Item-CVI>0.79 were revised. The overall scale of the questionnaire was excellent with an S-CVI/Ave of 0.94. We conclude that the questionnaire on the willingness-to-pay for prescription drug cost-sharing was developed and validated through expert consultation, item selection, and CVI. The questionnaire reviewed in this study had good content validity. As a follow-up, a new 42-item questionnaire was developed.
{"title":"Development of Questionnaire on Willingness-to-Pay for Health Insurance Cost-Sharing for Catastrophic Prescription Drugs","authors":"Diesty Anita Nugraheni, Satibi Satibi, Susi Ari Kristina, Diah Ayu Puspandari","doi":"10.22146/ijp.7173","DOIUrl":"https://doi.org/10.22146/ijp.7173","url":null,"abstract":"Prescription drug cost-sharing in Indonesia remains challenging because no valid willingness-to-pay (WTP) questionnaire for this cost-sharing is available. The aim of this study was to conduct item selection and evaluate the content validity of the questionnaire on the WTP for prescription drug cost-sharing under the national health insurance scheme in patients with catastrophic illnesses. The method was a cross-sectional study and used a three-step design, namely literature review, consultation with some health economics experts, and evaluation of content validity. This study involved 9 experts, consisting of academicians and health professionals who worked in a hospital, to perform content validation of a questionnaire on the WTP for prescription drug cost-sharing. This study used CVI (content validity index) and CVR (content validity ratio) for both individual item measurement and the overall scale. This study's results reveal a questionnaire comprising 47 items grouped into five domains: healthcare utilization information, participation in health insurance information, drug information, and cost-sharing scenarios. The questionnaire items were extracted from many sources. The items that could be used for the study should have an I-CVI of 0.79-1.00. There were three items removed because of criticisms from the experts and Item-CVI<0.79 and CVR<0.62. Those with Item-CVI>0.79 were revised. The overall scale of the questionnaire was excellent with an S-CVI/Ave of 0.94. We conclude that the questionnaire on the willingness-to-pay for prescription drug cost-sharing was developed and validated through expert consultation, item selection, and CVI. The questionnaire reviewed in this study had good content validity. As a follow-up, a new 42-item questionnaire was developed.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135134762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Howaida Abdelrahman, Ebtesam Essa, Gamal El Maghraby, Mona Arafa
Lamotrigine is an antiepileptic drug with slow dissolution rate which can reduce its oral bioavailability. In addition, it was reported to have first pass metabolism. Accordingly, the aim of this work was to enhance its dissolution rate utilizing co-crystallization technique to be suitable for incorporation in buccal dosage form. L-proline was selected as co-crystal co-former for enhancing dissolution in addition to its beneficial anticonvulsant properties. Formulations containing lamotrigine and L-proline at different molar ratios were prepared using ethanol assisted co-grinding. The prepared formulations were characterized using FTIR, X-Ray powder diffraction, differential scanning calorimetry and dissolution studies. The formulation recorded the highest dissolution rate was incorporated in fast disintegrating tablet for buccal use. Characterization techniques suggested the formation of lamotrigine-l-proline co-crystals with 1:2 molar ratio being optimum for interaction. This interaction resulted in significant enhancement in dissolution rate with the ratio of lamotrigine to proline at molar ratio of 1:4 showed greatest dissolution rate (% DE= 80.57). The prepared tablet utilizing lamotrigine and L-proline at molar ratio of 1:4 showed fast disintegration and rapid dissolution rate compared with control tablet containing lamotrigine alone. The study suggested L-proline as an efficient co-crystal co-former for enhancing dissolution rate of lamotrigine for buccal delivery.
{"title":"L-proline as co-crystal forming amino acid for enhanced dissolution rate of lamotrigine: Development of buccal tablet","authors":"Howaida Abdelrahman, Ebtesam Essa, Gamal El Maghraby, Mona Arafa","doi":"10.22146/ijp.6867","DOIUrl":"https://doi.org/10.22146/ijp.6867","url":null,"abstract":"Lamotrigine is an antiepileptic drug with slow dissolution rate which can reduce its oral bioavailability. In addition, it was reported to have first pass metabolism. Accordingly, the aim of this work was to enhance its dissolution rate utilizing co-crystallization technique to be suitable for incorporation in buccal dosage form. L-proline was selected as co-crystal co-former for enhancing dissolution in addition to its beneficial anticonvulsant properties. Formulations containing lamotrigine and L-proline at different molar ratios were prepared using ethanol assisted co-grinding. The prepared formulations were characterized using FTIR, X-Ray powder diffraction, differential scanning calorimetry and dissolution studies. The formulation recorded the highest dissolution rate was incorporated in fast disintegrating tablet for buccal use. Characterization techniques suggested the formation of lamotrigine-l-proline co-crystals with 1:2 molar ratio being optimum for interaction. This interaction resulted in significant enhancement in dissolution rate with the ratio of lamotrigine to proline at molar ratio of 1:4 showed greatest dissolution rate (% DE= 80.57). The prepared tablet utilizing lamotrigine and L-proline at molar ratio of 1:4 showed fast disintegration and rapid dissolution rate compared with control tablet containing lamotrigine alone. The study suggested L-proline as an efficient co-crystal co-former for enhancing dissolution rate of lamotrigine for buccal delivery.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135471281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ivans Panduwiguna, None Rani Sauriasari, None Ratu Ayu Dewi Sartika, None Woro Riyadina
Diabetes is a global problem that is increasingly higher from year to year. Diabetes-specific instruments so far can be well received by patients to evaluate specific aspects of their diabetic disease. This instrument is believed to be one of the best methods to evaluate certain characteristics in diabetic diseases. The purpose of the research is to identify and compare all validated diabetes-specific questionnaires. Researchers performed searches on three different electronic databases: PubMed, ScienceDirect, and Google Scholar. The study was selected covering cross-cultural adaptation and validation methodologies in Indonesia with type 1 and type 2 diabetes patients of all ages. After reviewing the full-text article, data related to psychometric characteristics are extracted from each selected study. Reliability is rated with Cronbach's (Cα). The initial search identified 1,576 studies. After the exception, 45 studies were put in for review. The questionnaires were grouped into 12 domains based on the focus of the study: adherence (n = 15), quality of life (n = 9), diabetes knowledge (n = 6), self-efficacy (n = 9), Attitude to diabetes (n = 2), emotional stress (n = 8), expectations (n = 1), perception of disease severity (n = 1), risk of developing diabetes (n = 1), family support (n = 3), diet (n = 1) and religiosity (n = 1)This study identifies and reviews all diabetes-specific questionnaires that have been validated for Indonesians to facilitate researchers to select the most appropriate instrument for each domain of interest in future research and clinical settings.
{"title":"A Diabetes-Specific Questionnaires Validated in Indonesia: A Systematic Review","authors":"Ivans Panduwiguna, None Rani Sauriasari, None Ratu Ayu Dewi Sartika, None Woro Riyadina","doi":"10.22146/ijp.6225","DOIUrl":"https://doi.org/10.22146/ijp.6225","url":null,"abstract":"Diabetes is a global problem that is increasingly higher from year to year. Diabetes-specific instruments so far can be well received by patients to evaluate specific aspects of their diabetic disease. This instrument is believed to be one of the best methods to evaluate certain characteristics in diabetic diseases. The purpose of the research is to identify and compare all validated diabetes-specific questionnaires. Researchers performed searches on three different electronic databases: PubMed, ScienceDirect, and Google Scholar. The study was selected covering cross-cultural adaptation and validation methodologies in Indonesia with type 1 and type 2 diabetes patients of all ages. After reviewing the full-text article, data related to psychometric characteristics are extracted from each selected study. Reliability is rated with Cronbach's (Cα). The initial search identified 1,576 studies. After the exception, 45 studies were put in for review. The questionnaires were grouped into 12 domains based on the focus of the study: adherence (n = 15), quality of life (n = 9), diabetes knowledge (n = 6), self-efficacy (n = 9), Attitude to diabetes (n = 2), emotional stress (n = 8), expectations (n = 1), perception of disease severity (n = 1), risk of developing diabetes (n = 1), family support (n = 3), diet (n = 1) and religiosity (n = 1)This study identifies and reviews all diabetes-specific questionnaires that have been validated for Indonesians to facilitate researchers to select the most appropriate instrument for each domain of interest in future research and clinical settings.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135164717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：